Epoprostenol

prostaglandin I2 receptor ; Homo sapiens







28 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35503651 The impact of nebulized epoprostenol and iloprost on hemoglobin oxygen affinity: an ex vivo experiment. 2022 Jun 1 1
2 32531060 Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. 2021 Mar 21 1
3 34741773 Cutaneous iontophoresis of vasoactive medications in patients with scleroderma-associated pulmonary arterial hypertension. 2021 Nov 6 1
4 32962984 International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. 2020 Oct 1
5 30982349 Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. 2019 May 21 1
6 29146573 Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension. 2018 Mar 1 1
7 28399721 The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. 2017 Jun 2
8 26946143 Stimulation of fat storage by prostacyclin and selective agonists of prostanoid IP receptor during the maturation phase of cultured adipocytes. 2016 Dec 2
9 26291199 Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. 2015 Sep 24 1
10 23109431 New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-G protein coupling. 2013 Jan 1
11 23457445 Molecular analysis of the prostacyclin receptor's interaction with the PDZ1 domain of its adaptor protein PDZK1. 2013 1
12 22969152 Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1. 2012 Nov 1
13 21606930 Non-conventional hemostatic risk factors for coronary heart disease in individuals with spinal cord injury. 2011 Aug 2
14 20522800 Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. 2010 Sep 1
15 19302827 Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. 2009 May 3
16 16672356 Developmental regulation of prostacyclin synthase and prostacyclin receptors in the ovine uterus and conceptus during the peri-implantation period. 2006 May 2
17 16723294 Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. 2006 May 5 2
18 16271145 A strategy using NMR peptide structures of thromboxane A2 receptor as templates to construct ligand-recognition pocket of prostacyclin receptor. 2005 Nov 4 1
19 15056772 Temporal expression and signalling of prostacyclin receptor in the human endometrium across the menstrual cycle. 2004 Jan 1
20 12193530 A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. 2002 Sep 1
21 9238054 Demonstration of a novel circulating anti-prostacyclin receptor antibody. 1997 Aug 5 1
22 9264479 Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. 1997 Aug 5 1
23 7532011 Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL. 1995 Feb 16 1
24 7543911 Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion. 1995 Sep 1
25 8016389 Biochemical and pharmacological activity of arene-fused prostacyclin analogues on human platelets. 1994 Mar 1
26 2477277 Induction of prostacyclin receptor expression in human erythroleukemia cells. 1989 Sep 11 1
27 2465947 The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level. 1988 1
28 2847246 Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor. 1988 Jun 1